Title: Epidemiology and Characteristics of MPXV Clade I cases in the WHO European

Region, 2024-2025

Authors: Ioannis Karagiannis[1], Jeffrey Pires[1], Pana Akhmetniyaz[1], Olivier le Polain

de Waroux[2], Bart Hoorelbeke[3], Bertrand Gagnière[4], Klaus Jansen[5], Chrysa Tsiara[6],

Derval Igoe[7], Maria Rosaria Campitiello[8], Catharina van Ewijk[9], Vítor Cabral

Veríssimo[10], Laura Santos Larrégola[11], Erik Sturegård[12,13], Céline Gardiol[14], Taliha

Karakök[15], Gareth J. Hughes[16], Marc-Alain Widdowson[1]

Author information and affiliations:

[1] Health Security Division, WHO Regional Office for Europe, Copenhagen, Denmark

[2] WHO Health Emergencies Programme, WHO headquarters, Geneva, Switzerland

[3] DG Preparedness and Response, Federal Public Service – Health, Food Chain Safety

and Environment, Brussels, Belgium

[4] Santé Publique France, Rennes, France

[5] Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin,

Germany

[6] National Public Health Organisation, Athens, Greece

[7] HSE – Public Health: National Health Protection Office Dublin, Ireland

[8] Head of the Department of Prevention, Research and Health Emergency, Ministry

of Health, Italy

[9] National Institute for Public Health and the Environment, Bilthoven, the

Netherlands

[10] Directorate-General of Health, Ministry of Health, Portugal

[11] Coordinating Centre for Health Alerts and Emergencies, Ministry of Health, Spain

[12] Department of Communicable Disease Control and Preparedness, Public Health

Agency of Sweden

[13] Department of Translational Medicine, Faculty of Medicine, Lund University,

Malmö, Sweden

[14] Section for Infection Control and Response Measures, Communicable Diseases

Division, Federal Office of Public Health, Bern, Switzerland

[15] Department of Communicable Diseases, General Directorate of Public Health,

Ministry of Health, Ankara, Türkiye

[16] Field Services, UK Health Security Agency, Leeds, United Kingdom

Contact author: Marc-Alain Widdowson widdowsonm@who.int

Abstract

BACKGROUND

A public health emergency of international concern (PHEIC) was declared in August

2024 following a sharp increase in mpox cases linked to the emergence of

monkeypox virus (MPXV) clade Ib.

AIM

To characterise imported and locally acquired mpox clade I cases reported in the

WHO European Region since August 2024, and to assess transmission patterns and

response measures.

METHODS

Between 14 August 2024 and 23 November 2025, we collected key information on

MPXV clade I infections reported by member states of the WHO European Region

through the International Health Regulations. We contacted reporting countries to

collect age, sex, travel history, most likely route of transmission, clinical course,

contacts and type of exposure, and implemented control and prevention measures.

RESULTS

Eighty-two cases of MPXV clade I infection were reported; forty-five were imported

and 37 were infections acquired in reporting member states. Seventy-nine were

typed as clade Ib and two as clade Ia. Most imported cases reported heterosexual or

close physical contact as possible exposure. Secondary transmission occurred in six

households. One healthcare worker was infected. Since October 2025, 17

autochthonous cases in men were most likely infected through sex with other men.

CONCLUSIONS

Imported cases of MPXV clade I infection were associated with limited household

transmission. The increase in autochthonous infections among men with recent

sexual contact with other men suggests undetected spread in Europe, that may

become sustained. Continued surveillance, case and contact investigation are

needed to understand MPXV clade I epidemiology and drivers of MPXV clade I

transmission in Europe.

Introduction

Two major genetic clades of monkeypox virus (MPXV) have been described: clade I,

historically associated with central Africa, and clade II, historically associated with

west Africa [1-2]. Before the recent multi-country outbreaks, cases outside Africa

were rare and associated with little or no onward transmission [2-3].

In 2020, the largest recorded outbreak of mpox due to MPXV clade I occurred in the

Democratic Republic of the Congo [4] and in 2022, a global mpox epidemic caused

by MPXV clade II prompted the World Health Organization (WHO) Director-General

to declare a Public Health Emergency of International Concern (PHEIC) [5]. The

monthly number of reported global cases peaked at approximately 30,000 cases in

August 2022 [6], followed by a decline in cases globally and in Europe [7] and in

May 2023 the PHEIC was lifted [8]. Since September 2023, the Democratic Republic

of the Congo has seen a sharp increase in the reported number of mpox cases,

linked to both the emergence of a distinct new strain, MPXV clade Ib, and a rise in

cases caused by infection with previously circulating MPXV clade Ia [9, 10]. Earlier

evidence, including a 2022 meta-analysis, suggested that MPXV clade I may be

associated with higher case-fatality than clade II [9, 11]. The newly identified clade

Ib rapidly spread to neighbouring African countries and elsewhere. Initial reports

from Democratic Republic of the Congo indicated sustained person-to-person

transmission, including through heterosexual sex. For this reason, WHO declared

mpox a PHEIC for a second time on 14 August 2024 [12], which was lifted in

September 2025 [13]. The first case of MPXV clade Ib infection outside of Africa was

reported by Sweden on the next day [14, 15]. Between January 2024 and 7

November 2025, 17 countries in the WHO African Region and 26 countries in all

other regions have reported MPXV clade Ib cases [6], with the European region

reporting most MPXV clade I cases. Evidence from imported cases [16, 17] and

outbreaks in Africa [10, 18] indicates that MPXV clade I transmission may occur both

within and outside sexual networks, including through skin-to-skin contact [19].

Rapid investigation of MPXV clade I cases and timely public health response are

essential to prevent further spread, provide key data on the epidemiology of MPXV

clade I and inform risk assessments for Europe and comparable settings worldwide.

In this paper, we describe MPXV clade I cases reported in the WHO European

Region since August 2024 to gain a better understanding of the characteristics and

epidemiology of MPXV clade I cases in Europe.

Methods

Data collection

The WHO Office for the European Region collected information on MPXV clade I

cases reported in line with WHO standing recommendations for mpox [20] through

International Health Regulations (IHR) channels [21] between 14 August 2024 and

23 November 2025. Reporting MS were contacted either by email or teleconferences

together with relevant colleagues from the European Centre for Disease Prevention

and Control (ECDC) using a standard set of questions to collect information on age,

sex, travel history, likely route of transmission, clinical course and hospitalisation,

contacts, and implemented control and prevention measures.

Case definitions

Confirmed cases were defined as persons with or without symptoms, with laboratory

confirmation of MPXV clade I by molecular detection in any clinical specimen,

including lesion swabs and upper respiratory tract specimens. Probable cases were

defined as persons with symptoms compatible with mpox who were

epidemiologically linked to a confirmed case, but without laboratory confirmation of

MPXV clade I.

Cases were classified as imported if their personal history indicated that they had

contracted infection outside the reporting MS in the 21 days preceding symptom

onset during national case investigation activities or, otherwise, as autochthonous.

Clusters of cases were defined as individual cases who were epidemiologically linked.

Laboratory confirmation

Laboratory confirmation and clade classification were performed by national or

subnational laboratories in the reporting Member States (MS) as part of routine

public health investigation. Cases included in this analysis had molecular

confirmation of MPXV clade I by PCR-based testing performed on clinical specimens.

Subclade assignment (Ia/Ib) was based on national laboratory typing and, where

available, sequencing or clade-specific molecular characterisation. Laboratory

approaches were not standardised across countries. Published descriptions of

microbiological methods for selected European cases are available elsewhere

[14,17,22-24].

Statistical analysis

We described cases by age, sex, travel history, possible exposures, most likely route

of transmission, hospitalisation and clinical course, care-seeking behaviour, diagnosis

delays, HIV status or other clinical comorbidities that cause immunosuppression,

prior vaccination for mpox, number of contacts, and information on implemented

control and preventive measures. Continuous variables across case groups were

compared using the Kruskal-Wallis test using Stata v19.5. Percentages have been

rounded to the nearest decimal.

Results

As of 23 November 2025, 13 of the 53 MS reported one probable and 81 confirmed

cases of MPXV clade I infection to the WHO Regional Office for Europe; one case

reported by Türkiye and one reported by the Republic of Ireland were typed as clade

Ia, and the remaining 79 were typed as MPXV clade Ib; the MPXV clade Ia case

reported by the Republic of Ireland has been described elsewhere [22]. The other, a

probable case reported by the Republic of Ireland, was imported and had close

contact with a subsequently confirmed case of MPXV clade Ib infection. One case

with travel history to Asia initially notified as MPXV clade Ib was later found to be a

recombinant virus containing elements of both clade Ib and IIb [23]. Of the 82

cases, 45 (54.9%) were imported and 37 (45.1%) were autochthonous. Likely

countries of infection included Uganda (N=11), Democratic Republic of the Congo

(N=6), Rwanda (N=5), the United Republic of Tanzania (N=5), Kenya (N=3), the

United Arab Emirates (N=3), Thailand (N=2), the Netherlands (N=2), Malaysia

(N=1), Pakistan (N=1), Viet Nam (N=1), Angola (N=1), "East Africa" (N=1), and

"Central Africa" (N=1). One case had travelled to Rwanda, Uganda, and United

Republic of Tanzania within 21 days before symptom onset, and one case had

travelled to both Egypt and United Arab Emirates, but case history suggests

transmission most likely occurred in the latter. Of the 37 cases infected in Europe,

17 were secondary cases of one of seven imported cases or an already known

autochthonous case, and a further 20 cases were not related to any reported case

(Figure 1).

FIGURE 1: Reported MPXV clade I cases and clusters, 14 August 2024 – 23
November 2025, WHO Regional Office for Europe (N=82).

Of the 45 imported cases, 43 were male and two were female. Age was known for
38 cases, while only the 10-year age group was known for another six; the median
age was 36.5 years (range 18-64 years). The most likely route of infection was
assessed as sexual contact for 26 of 45 imported cases, other intimate physical
contact (e.g. massage, sauna services) for five and unknown for the remaining 14
cases (Table 1). Among the 25 imported men reported to have acquired infection
sexually, the sex of the most likely infecting partner was known for 17; in 12 cases
the partner was female and in five the partner was male. One additional imported
case with sexual exposure was female.

Information on hospitalisation was available for 79 cases, of whom 18 (22.8%) were
hospitalised; four, among whom one child, were admitted for clinical reasons and 13
for isolation or other non-mpox-related reasons. The reason for hospitalisation was
not available for one hospitalised case. Prior vaccination status was available for 51
cases, among whom four had been vaccinated before symptom onset. The exact
vaccine product was not available. HIV status was known for 44 cases, among whom
six were living with HIV. Information on immunocompromising conditions other than
HIV was available for 36 cases, none of whom were reported to be
immunocompromised. All cases have recovered.

Of the 37 autochthonous cases, 25 were male and 10 were female; sex information
was unavailable for two cases. Thirteen were household contacts of imported cases.

Of these 13 secondary cases in households, seven were below the age of 15 years

(three were aged 1-4 years, two were aged 5-9 years, and the remaining two were

10-14 years old). Four of the 13 household cases were partners of index cases (one

of whom was a probable case) and were reported to have contracted mpox sexually

from their partners; the remaining nine likely acquired infection through household

contact. One of the cases infected in Europe was a healthcare worker who had cared

for a hospitalised case before mpox was included in the differential diagnosis.

Standard IPC precautions appropriate to the initial working diagnosis were used,

including gown/apron, gloves and a surgical mask; no breach of PPE or needlestick

injury was reported. Contact and airborne-based precautions were introduced after

mpox was suspected (Table 1) [24].

Of the 24 autochthonous cases with no clear exposure to a reported case, one had

no travel history but reported contact with her male partner and another family

member who had both returned from a central African country in the previous 21

days; neither of them had reported symptoms compatible with MPXV infection. The

exact source of infection for the other cases remains unknown (Table 1). Among 44

men who contracted mpox sexually, information on the sex of the most likely

infecting partner was available for 40 of them; among these, 21 reported having

most likely acquired the infection from other men most likely in the Netherlands

(N=11), Spain (N=8), Malaysia (N=1), and United Arab Emirates (N=1). No men

who acquired MPXV clade Ib through sexual contact with other men were reported

to WHO before October 2025. Six of the 11 cases reported by the Netherlands and

one reported by Belgium reported having attended the same sex venue in

Amsterdam. Of these six cases reported by the Netherlands, four attended the

venue on the same date, and the remaining two on two different dates; according to

the national investigation, all six had attended within one incubation period prior to

symptom onset, suggesting that they most likely acquired infection there.

TABLE 1: Reported probable mode of transmission of MPXV clade I cases,

WHO Member States, 14 August 2024 – 23 November 2025 (N=82)

Probable mode of transmission	Imported cases (N=45)	Autochthonous cases (N=37)		All cases (N=82)
		Household cases (N=13)	Other cases (N=24)	
Sexual contact	26 (57.8%)	4 (30.8%)	19 (79.2%)	49 (59.8%)
Other contact in household	0 (0%)	9 (69.2%)	0 (0%)	9 (11.0%)
Close physical contact (e.g. sauna, spa, massage)	5 (11.1%)	0 (0%)	0 (0%)	5 (6.1%)
Healthcare setting	0 (0%)	0 (0%)	1 (4.2%)	1 (1.2%)
Unknown	14 (31.1%)	0 (0%)	4 (16.7%)[a]	18 (22.0%)

[a] One of these cases reported contact with family members who had travelled to an
outbreak-affected country in Central Africa.

Of the 45 imported cases, information on whether the individual was returning to a
household with other residents was available for 34; of these, 25 returned to
households with other residents. Transmission was identified in six of these 25
households. Within these six households, 13 additional cases occurred among 33
household contacts (overall attack rate: 39.4%, range 0-100%). Two household
cases were determined to be possible second-generation transmission events; in one
household, the case had symptom onset in January 2025 following two cases with
symptom onset in the same household in December 2024, although transmission
through fomites or an unidentified fourth household case could not be excluded. On
another occasion, a probable imported case infected his wife sexually (attack rate:
12.5%, 1/8 susceptible household contacts). The wife then likely infected one of the

remaining seven susceptible household members through close physical contact

(secondary attack rate: 14.3%, 1/7). Of 37 imported cases with information

available, 15 travelled to Europe by air while symptomatic or with rash and, in at

least one case, with an uncovered rash on their arms.

MS reported that contacts of mpox cases were identified and risk classified in line

with WHO [25] or national guidance. However, follow-up of travel-related contacts

was not implemented consistently across MS; for one imported case, national health

authorities asked the airline to contact the co-passengers who had been exposed to

the case on a 1 hour flight.Information on the number of contacts in travel and

school settings was sparse, and no secondary case was reported among travel or

school contacts.

Where information was available (N=68), subclade assignment was reported at a

median of 9.5 days after symptom onset (-1 to 74 days); two patients were

diagnosed before symptom onset due to active follow-up following household

exposure. In these cases, MPXV was detected by PCR from upper respiratory tract

specimens and, where lesions subsequently appeared, lesion specimens. However,

specimen source and testing approaches were not systematically available for all

contacts across MS.

Contacts of already reported cases sought or received care quicker and were

diagnosed sooner than imported cases or those autochthonous cases with no

reported exposure to a known case (Table 2); nonetheless, contacts of known cases

still took a median of 4 days after symptoms onset to seek care.

TABLE 2: Time to seeking care and to diagnosis of reported clade I MPXV

cases, WHO EURO member states, 14 August 2024 – 23 November 2025

	Median delay from symptom onset to seeking care (range) (N=52)	**Median delay from seeking care to subclade assignment (range)**	**Median delay from symptom onset to subclade assignment (range) (N=68)**

	(N=49)		
Imported cases	5.0 (1 to 20) days	6.0 (0 to 70) days	11 (2 to 74) days
Autochthonous cases with contact to already reported cases	4.0 (0 to 9) days	5.0 (2 to 7) days	6.0 (-1 to 14) days
Autochthonous cases without contact to already reported cases	3.0 (2-15) days	4.5 (1 to 12) days	9.0 (4 to 21) days
All cases	5.0 (0 to 20) days	6.0 (0 to 70) days	9.5 (-1 to 74) days
Kruskal-Wallis test p-value	0.3350	0.5132	0.0064

Discussion

Since the declaration of a PHEIC in August 2024 and until 23 November 2025, 82

confirmed MPXV clade I cases have been reported in 13 member states of the WHO

European Region. Until October 2025, most cases were imported, with limited

secondary and possibly tertiary household transmission involving partners and

children. Since October 2025, an increasing number of cases without links to travel

have been reported, especially among men who have sex with men, suggesting

circulation of the virus in Europe [26, 27]. Sexual transmission of MPXV clade Ib,

especially in MSM networks, appears to have become an important route of

transmission in Europe in recent months. Experience from MPXV clade IIb suggests

that the spillover risk for the general population remains limited [7].

We describe here also two cases of MPXV clade Ia infection, both with recent travel

to the Democratic Republic of the Congo. One of the sequences contained a

mutational signature widely reported for MPXV clade IIb virus genomes during the

2022-2023 global outbreak. The presence of this host-driven mutagenesis pattern in
a MPXV clade Ia virus suggests substantial person-to-person transmission [28].

Follow-up of flight passengers was implemented inconsistently across MS, which
limited assessment of transmission risk during air travel. No secondary cases were
identified among reported travel contacts in available data, in line with published
evidence suggesting a very low risk of mpox transmission during air travel for MPXV
clade IIb [29]. Disentangling transmission routes in household settings was
complicated by the sensitive nature of the infection and the multiple possibilities of
contact and fomite use. This underlines the importance of reinforcing existing WHO
recommendations for household contacts [25]. The healthcare-associated case
occurred before mpox was suspected clinically, when the patient was managed using
precautions appropriate to an alternative working diagnosis rather than mpox-
specific precautions [24]. This highlights the importance of considering mpox early in
the differential diagnosis of compatible presentations in healthcare settings.

MPXV clade I infections have been previously considered more severe than clade II
infections [9, 30]. However, our data showed that reported cases in the European
Region were much less severe than those reported in African countries; no deaths
were observed, and among the 79 cases for whom hospitalisation status was
available, only four were hospitalised for clinical reasons, including one child. This is
consistent with more recent data indicating that, in areas where MPXV clade Ib has
become endemic, CFRs have been reported to be below 1% [9]. This may reflect not
only differences in the affected populations and transmission patterns, but also
earlier health care seeking and access to supportive care. Interpretation of
underlying clinical risk factors was limited by incomplete data; among cases with
available information, six were reported to be living with HIV, none were reported to
be immunocompromised other than HIV, and four had received mpox vaccination
before symptom onset.

Since 2023, the outbreak of MPXV clade I in the Democratic Republic of the Congo
has affected younger age groups, including children [10, 18]. In our series, sexual
contact was the most likely route of transmission for 26 of 45 imported cases.
Among the 25 men who were judged to have acquired the infection sexually

overseas, the sex of the most likely infecting partner was known for 17, and in 12 of
these cases the partner was a woman. Of the 18 locally acquired MPXV clade Ib
cases in Europe, seven were among children under 15 years, whereas since 2022,
only 38 locally acquired clade II cases in this age group, despite more than 33,000
cases of clade IIb in MSM [6]. This may reflect differences between the
predominantly non-sexual household transmission observed following imported
MPXV clade I cases, including infections among children, and the ongoing sexual
transmission of clade IIb mpox in MSM networks in the WHO European Region. More
data is needed to see whether these differences reflect contact patterns, virologic
factors, or both.

Although active follow-up of contacts supported the identification of secondary cases
in Europe, healthcare-seeking and diagnostic delays, especially among index cases,
may have contributed to onward transmission. Delays were substantial in our case
series, with a median of 6 days from seeking care to virus subclade assignment and
up to 70 days among imported cases. Clinicians in primary and acute care should
consider mpox in patients with compatible symptoms regardless of travel history,
and request PCR with clade-specific typing at initial testing, given autochthonous
MPXV clade Ib circulation in Europe. The 4-day gap between symptom onset and
seeking care among contacts of known cases was notable despite active follow-up.

The outbreak in Central and East Africa, albeit declining, is ongoing despite control
efforts, including vaccination. While MPXV clade I continues to circulate in these
regions, further importations into the European Region are likely. In Europe, the
epidemiology of MPXV clade I is changing. Early in the observation period, most
cases were imported, often following heterosexual exposure in outbreak-affected
countries, with only limited onward transmission, mainly in household settings. More
recently, however, an increasing number of autochthonous cases have been
reported among MSM, often without clear epidemiological links to known imported
cases, suggesting a shift from isolated importation events towards circulation within
MSM sexual networks such as for clade IIb. The clustering of cases linked to a sex
venue in Amsterdam further supports this interpretation. Similar locally acquired
MPXV clade Ib transmission among MSM and their networks was also reported in the

United States around the same period [31]. Uncertainties remain regarding the
extent of silent importations, age-specific risk, secondary attack rates, and vaccine-
derived protection. MPXV clade II transmission continues in Europe at low levels of
100-300 cases a month, mainly in MSM sexual networks [6, 7]. An immediate
priority in Europe remains to reduce the risk of sustained MPXV clade I transmission
through early detection, interruption of transmission, and protection of groups at
higher risk, in line with the WHO European Region goal of mpox elimination. As
more recent MPXV clade Ib spread in Europe has been largely driven by MSM sexual
networks rather than isolated importations, understanding current immunity levels
among high-risk groups is important. Published estimates suggest that mpox vaccine
coverage among MSM in Europe is heterogeneous and incomplete, with ECDC citing
EMIS-2024 data showing two-dose self-reported coverage ranging from 0.5% to
37.9% across EU/EEA countries, which supports continued emphasis on vaccination
in higher-risk groups [32]. Other modelling analyses also point to maintenance of
high-risk behaviours among MSM that should be tackled through awareness
campaigns [33]. Although the PHEIC was lifted in September 2025, WHO Standing
Recommendations [20] remain important for countries to mitigate the establishment
of MPXV clade I transmission.

Continued global collaboration on genomic surveillance with subtyping, early case
identification, early diagnosis and systematic contact tracing, including timely cross-
border information sharing, remain essential to reduce the risk of sustained MPXV
clade I transmission in Europe and to understand virological evolution [7, 25].
Strengthening diagnostic capacity, including subtyping, is critical to detect and
monitor emerging variants and guide appropriate public health action [28, 34]; the
recombinant virus reported by the United Kingdom would not have been identified
without routine genomic surveillance [23]. Given the observed cases among a
healthcare worker and within an MSM network, countries in Europe should ensure
robust infection prevention control in healthcare facilities and sustain engagement
with MSM communities.

Finally, renewed efforts should also ensure that vaccination, clear information on
infection risk, and behavioural measures to reduce it reach affected groups. These

include reducing the number of partners and safer sex practices, especially for

individuals who may play a disproportionately high role in transmission within MSM

networks.

This analysis has several limitations. We relied on case-based information reported

to WHO by MS, and data completeness and detail varied between countries. As WHO

works primarily with nationally reported data, some variables were not consistently

available or could not be shared in sufficient detail. Laboratory approaches, sample-

taking and contact follow-up practices were not standardised across the Region, and

countries differed in MPXV testing algorithms, specimen types, and access to clade-

specific typing or sequencing. Exposure histories were based on case interviews, and

may therefore be affected by recall and social desirability bias, particularly for

sensitive exposures. Differences in case detection, contact tracing and follow-up may

also have influenced the reported distribution of transmission routes and clusters.

Finally, undiagnosed mild or asymptomatic infections and unrecognised transmission

chains are likely to have resulted in under-ascertainment.

Conclusions

Most early MPXV clade I cases reported in the WHO European Region were imported

and resulted in limited onward transmission, mainly in household settings. More

recently, autochthonous cases among men exposed through sex with other men

suggest changing transmission patterns and spread within MSM sexual networks in

Europe. Severe clinical outcomes were uncommon in this case series, with no deaths

observed and few hospitalisations for clinical reasons. Continued surveillance, early

diagnosis, subclade-specific testing, case investigation and contact tracing remain

essential to reduce the risk of further spread and possible establishment of MPXV

clade I in Europe. Targeted vaccination, risk communication and engagement with

affected communities should remain central in the public health response.

Acknowledgments

We wish to thank Xanthi Andrianou and Gianfranco Spiteri from the European Centre
for Disease Prevention and Control for critically reviewing this paper, as well as all
colleagues in Europe working on mpox response at the national and subnational
level for their continued contributions to surveillance.

References

1.   Heymann DL, Szczeniowski M, Esteves K. Re-emergence of monkeypox in
Africa: a review of the past six years. Br Med Bull. 1998;54(3):693-702.

2.   Petersen E, Abubakar I, Ihekweazu C, Heymann D, Ntoumi F, Blumberg L, et
al. Monkeypox - Enhancing public health preparedness for an emerging lethal human
zoonotic epidemic threat in the wake of the smallpox post-eradication era. Int J
Infect Dis. 2019;78:78-84.

3.   Centers for Disease Control and Prevention. Multistate outbreak of
monkeypox--Illinois, Indiana, and Wisconsin, 2003. MMWR Morb Mortal Wkly Rep.
2003;52(23):537-40.

4.   World Health Organization. Disease Outbreak News - Monkeypox - Democratic
Republic of the Congo. 2020. 2025-04-16. Available from:
https://www.who.int/emergencies/disease-outbreak-news/item/monkeypox-
democratic-republic-of-the-congo.

5.   World Health Organization. WHO Director-General declares the ongoing
monkeypox outbreak a Public Health Emergency of International Concern. 2022.
2025-04-16. Available from: https://www.who.int/europe/news/item/23-07-2022-
who-director-general-declares-the-ongoing-monkeypox-outbreak-a-public-health-
event-of-international-concern.

6.   World Health Organization. Global Mpox Trends. 2025. 2025-04-16. Available
from: https://worldhealthorg.shinyapps.io/mpx_global/#trends-in-cases.

7.   Vaughan AM, Afzal M, Nannapaneni P, Leroy M, Andrianou X, Pires J, et al.
Continued circulation of mpox: an epidemiological and phylogenetic assessment,
European Region, 2023 to 2024. Euro Surveill. 2024;29(27).

8.   World Health Organization. Fifth Meeting of the International Health
Regulations (2005) (IHR) Emergency Committee on the Multi-Country Outbreak of

mpox (monkeypox). 2023. Available from: https://www.who.int/news/item/11-05-
2023-fifth-meeting-of-the-international-health-regulations-%282005%29-
%28ihr%29-emergency-committee-on-the-multi-country-outbreak-of-monkeypox-
%28mpox%29.

9.   Vakaniaki EH, Kacita C, Kinganda-Lusamaki E, O'Toole Á, Wawina-Bokalanga
T, Mukadi-Bamuleka D, et al. Sustained human outbreak of a new MPXV clade I
lineage in eastern Democratic Republic of the Congo. Nat Med. 2024;30:2791-5.

10.   European Centre for Disease Prevention and Control. Risk assessment for the
EU/EEA of the mpox epidemic caused by monkeypox virus clade I in affected African
countries. 2024. 2025-12-17. Available from:
https://www.ecdc.europa.eu/en/publications-data/risk-assessment-mpox-epidemic-
monkeypox-virus-clade-i-africa.

11.   DeWitt ME, Polk C, Williamson J, Shetty AK, Passaretti CL, McNeil CJ, et al.
Global monkeypox case hospitalisation rates: A rapid systematic review and meta-
analysis. eClinicalMedicine. 2022;54.

12.   World Health Organization. WHO Director-General declares mpox outbreak a
public health emergency of international concern. 2024. Available from:
https://www.who.int/europe/news/item/16-08-2024-who-director-general-declares-
mpox-outbreak-a-public-health-emergency-of-international-concern.

13.   World Health Organization. WHO Director-General's opening remarks at the
media briefing – 5 September 2025. 2025. 2025-09-11. Available from:
https://www.who.int/news-room/speeches/item/who-director-general-s-opening-
remarks-at-the-media-briefing---5-september-2025.

14.   Treutiger C-J, Filén F, Rehn M, Aarum J, Jacks A, Gisslén M, et al. First case of
mpox with monkeypox virus clade Ib outside Africa in a returning traveller, Sweden,
August 2024: public health measures. Euro Surveill. 2024;29(48):2400740.

15.   World Health Organization. Disease Outbreak News - Mpox - Sweden. 2024.
2025-09-11. Available from: https://www.who.int/emergencies/disease-outbreak-
news/item/2024-DON531.

16.   Biller M, Lais J, Esser S, Sammet S. Unusual case of non-sexual Mpox
transmission in a heterosexual woman. Infection. 2025.

17.   Alvi MI, Kliner M, Welfare W, Gordon NC, Thomas S, Padfield S, et al. Case

series of the first five human infections with monkeypox virus clade Ib and report on

the public health response, United Kingdom, October to November 2024. Euro

Surveill. 2025;30(10):2500131.

18.   Malembi E, Escrig-Sarreta R, Ntumba J, Beiras CG, Shongo R, Bengehya J, et

al. Clinical presentation and epidemiological assessment of confirmed human mpox

cases in DR Congo: a surveillance-based observational study. Lancet.

2025;405(10490):1666-75.

19.   Cabanillas B, Murdaca G, Guemari A, Torres MJ, Azkur AK, Aksoy E, et al.

Monkeypox 2024 outbreak: Fifty essential questions and answers. Allergy.

2024;79(12):3285-309.

20.   World Health Organization. Extension of standing recommendations for mpox

by the Director-General of WHO. 2025. Available from:

https://www.who.int/publications/m/item/extension-of-standing-recommendations-

for-mpox-by-the-director-general-of-who.

21.   World Health Organization. International Health Regulations (2005) as

amended in 2014 and 2022. 2022. Available from:

https://apps.who.int/gb/bd/pdf_files/IHR_2022-en.pdf.

22.   Dowling-Cullen C, Fahey L, Carr M, Keogan B, Hebert J, Muhamad Fauzi SM,

et al. Mpox due to monkeypox virus clade Ia infection detected outside of Africa: a

case study. Communications Medicine. 2025.

23.   UK Health Security Agency. New mpox strain identified in England. 2025.

Available from: https://www.gov.uk/government/news/ukhsa-detects-first-case-of-

clade-ib-mpox.

24.   McLoughlin M, Fahey L, Carr M, Caceda B, Igoe D, Dean J, et al. Nosocomial

transmission in a monkeypox virus clade Ib outbreak, Ireland, August to October

2025. Euro Surveill. 2025;30(50):2500926.

25.   World Health Organization. Surveillance, case investigation and contact

tracing for mpox: interim guidance, 27 November 2024. 2024. Available from:

https://www.who.int/publications/i/item/B09169.

26.   World Health Organization. Multi-country outbreak of mpox, External situation

report #59 - 30 October 2025. 2025. Available from:

https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report--59---30-october-2025.

27.   European Centre for Disease Prevention and Control. Communicable disease threats report. Week 44, 25-31 October 2025. 2025. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Communicable-disease-threats-report-week-44-2025.pdf.

28.   O'Toole Á, Neher RA, Ndodo N, Borges V, Gannon B, Gomes JP, et al. APOBEC3 deaminase editing in mpox virus as evidence for sustained human transmission since at least 2016. Science. 2023;382(6670):595-600.

29.   Delea KC, Chen TH, Lavilla K, Hercules Y, Gearhart S, Preston LE, et al. Contact Tracing for Mpox Clade II Cases Associated with Air Travel — United States, July 2021–August 2022. MMWR Morb Mortal Wkly Rep. 2024;73(35):758-62.

30.   Likos AM, Sammons SA, Olson VA, Frace AM, Li Y, Olsen-Rasmussen M, et al. A tale of two clades: monkeypox viruses. Journal of General Virology. 2005;86(10):2661-72.

31.   Tang EC, Haw M, Kulkarni S, Johnson E, Gigante CM, Balanji N, et al. Detection of community transmission of clade Ib mpox virus in the United States. NEJM Evidence. 2026;5(2).

32.   European Centre for Disease Prevention and Control. Threat Assessment Brief: Detection of autochthonous transmission of monkeypox virus clade Ib in the EU/EEA. 24 October 2025. Stockholm: ECDC; 2025. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/mpox-TAB-October-2025.pdf

33.   Xiridou M, van Wees DA, Adam P, Miura F, Op de Coul E, Reitsma M, et al. Combining mpox vaccination and behavioural changes to control possible future mpox resurgence among men who have sex with men: a mathematical modelling study. BMJ Public Health. 2025;31;3(2):e002682.34.   Atkinson B, Gould S, Nicholls I, Manzoor KN, Smith J, Hindle AJ, et al. Air and surface sampling for clade Ib monkeypox virus in United Kingdom hospitals, 2024 to 2025. Euro Surveill. 2025;30(19):2500288.